NeuroSense shares are trading lower. The company announced filing of a patent application with USPTO covering methods of treating TBI and related central nervous system injuries with the combination of ciprofloxacin and celecoxib.

NeuroSense Therapeutics Updates Health Canada Filing Timeline for PrimeC

NeuroSense Therapeutics announced it will delay its New Drug Submission (NDS) for PrimeC to March 2027 to incorporate new neurofilament light chain (NfL) analysis and additional Phase 2b data.

HC Wainwright Downgrades NeuroSense Therapeutics to Neutral

HC Wainwright & Co. downgraded NeuroSense Therapeutics from Buy to Neutral on November 2, 2026.

NeuroSense to Present Clinical and Biomarker Data at NEALS 2026

NeuroSense Therapeutics announced it will present integrated clinical and biomarker findings that are informing the next phase of development for its lead ALS drug candidate, PrimeC, at the 2026 NEALS Consortium Annual Meeting.

Neurosense Therapeutics Inks Collaboration Agreement To Advance Supply Of PrimeC To Treat Amyotrophic Lateral Sclerosis

NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib

The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term consequences, such as chronic

NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases,